Oat beta-glucans and the glucose peak: a new health claim is on its way
Posted: March 11, 2026 Filed under: Food, Health claims Comments Off on Oat beta-glucans and the glucose peak: a new health claim is on its way
You have probably experienced it: that familiar afternoon slump after a lunch heavy on pasta or bread. Blood sugar spikes sharply after a carbohydrate-rich meal, only to drop again shortly after, leaving you tired and unfocused. This postprandial glucose peak is not just a matter of energy levels; it is increasingly a focus of nutrition science and, as it turns out, of EU food law.
Positive outcomes in the EU health claim authorisation process are rare: the EU Register of Health Claims currently lists only 262 authorised health claims, against 2,067 that were not authorised. Regulation (EC) No 1924/2006 (hereinafter: Claims Regulation) harmonises the provisions relating to nutrition and health claims made on food and establishes rules governing the authorisation of health claims across the EU. Health claims are prohibited unless they comply with the requirements of the Claims Regulation, are authorised in accordance with it, and are included in the lists of authorised claims. The majority of health claim applications fail at the scientific hurdle. That alone makes a January 2026 positive opinion from the European Food Safety Authority (EFSA) on oat beta-glucans noteworthy. But there is a second reason this opinion stands out: the application was submitted under article 13(5) of the Claims Regulation. This route is rarely used, and even more rarely with success. At present, only 8 claims have been successfully evaluated via that route.
Article 13(1) versus article 13(5)
Most authorised health claims reached the permitted list via article 13(1) of the Claims Regulation, relating to general function claims. As an example “calcium is needed for the maintenance of normal bones” could be mentioned. These claims are based on generally accepted scientific evidence. Article 13(5) also target general function claims but through a fundamentally different route: it is reserved for claims based on newly developed scientific evidence. Unlike article 13(1), an applicant under article 13(5) must submit an individual application and bear the full burden of demonstrating that the claim is supported by newly developed scientific evidence. It is precisely this route that is at issue in the January 2026 EFSA opinion discussed below.
A new positive scientific opinion on oat beta-glucans
The Swedish industrial research centre ScanOats submitted a health claim for authorisation pursuant to article 13(5) of the Claims Regulation. The health claim was submitted via the Competent Authority of Ireland, and the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of this claim relating to oat beta-glucans and the reduction of postprandial glucose peaks. In its opinion, the EFSA Panel concludes that a cause-and-effect relationship has been established between the consumption of oat beta-glucans and the reduction of postprandial blood glucose peaks. In doing so, the Panel delivers a positive scientific opinion: a crucial step in the authorisation process, though formal authorisation remains with the European Commission.
How does this claim differ from the 2012 authorised health claim?
In its current opinion, the EFSA Panel considers that the following wording reflects the scientific evidence: ‘Consumption of beta-glucans from oats contributes to the reduction of the glucose peak after a meal’. This wording differs from the health claim that was already authorised back in 2012, which reads: ‘Consumption of beta-glucans from oats or barley as part of a meal contributes to the reduction of the blood glucose rise after that meal’. The difference is scientifically and legally significant. Also, the current claim seems easier to understand for the average consumer and, from a commercial point of view, is therefore more attractive.
The first claim focused on the overall rise and fall of glucose over time. The current claim focuses specifically on how high the blood sugar spike gets at its highest point. Because this concerns a different, more precise endpoint supported by new scientific evidence, a fresh authorisation procedure was required.
In order to bear the current claim, food or meals should contain at least 30 grams of available carbohydrates per portion and at least 3 grams of beta-glucans from oats for each 30 grams of available carbohydrates.
Status of this 2026 opinion
It is important to note that a scientific opinion of the EFSA Panel is not an authorisation yet. Following a positive EFSA opinion, the European Commission must still draw up a draft implementing regulation to add the claim to the EU register of permitted health claims. That proposal goes through a comitology procedure involving the Member States, after which the Commission formally adopts and publishes the regulation in the Official Journal of the EU. Only at that point is the claim officially authorised and may it lawfully appear on product labels.
The field is in full development
This latest development illustrates that the field of nutrition and health claims in the EU is far from static. New science can open doors that were previously closed, provided the evidence meets EFSA’s demanding standards. This 2026 opinion on oat beta-glucans is a prime example: built on 16 human intervention studies, it has cleared that bar under the demanding article 13(5) route. Successful article 13(5) applications are rare, but this EFSA opinion is a reminder that the route exists and that it can work. The next steps are now in the hands of the European Commission. For manufacturers, regulators and legal practitioners alike, this is a development worth following closely.
Image is by freepik.
EU Biotech Act and Food and Feed Safety Simplification Omnibus: what’s in it for the food and feed sector?
Posted: January 8, 2026 Filed under: Food Comments Off on EU Biotech Act and Food and Feed Safety Simplification Omnibus: what’s in it for the food and feed sector?A new era for biotechnology innovation
December 2025 brought not one but two major regulatory proposals from the European Commission: the long-awaited first part of the EU Biotech Act and the Food and Feed Safety Simplification Omnibus. Together, these proposals signal a fundamental shift in how the EU approaches biotechnology and food innovation.
The EU Biotech Act aims to strengthen the competitiveness of the EU biotechnology sector whilst maintaining the highest safety standards for people, animals and the environment. The Food and Feed Safety Simplification Omnibus complements this by proposing amendments to ten existing regulations, simplifying procedures, reducing administrative burdens and accelerating market access for innovative products.
Whilst the EU Biotech Act focuses primarily on health biotech, both proposals contain significant changes for the food and feed sector. In this blog, we break down what these two proposals mean for food and feed businesses, so you can start 2026 fully up to speed!
EU Biotech Act
Expanded pre-submission advice and EFSA’s broader mandate
If it is up to the European Commission, the days of incomplete dossiers and lengthy EFSA procedures are numbered. Under the EU Biotech Act proposal, article 32a(1) of the General Food Law Regulation (GFL) will be revised. Whereas EFSA previously only provided advice regarding procedural aspects of the application for innovative foods or the notification thereof, this is now being expanded to include advice on the design of studies and testing strategies to support such an application or notification. This is particularly valuable for SMEs, helping them submit more complete dossiers and shorten time-to-market.
Additionally, EFSA’s general mandate in the field of human nutrition is being adjusted. Article 22(5)(a) GFL is being amended from “scientific advice and scientific and technical support on human nutrition in relation to Community legislation” to simply “scientific advice and scientific and technical support on human nutrition”. By removing the restriction “in relation to Community legislation”, EFSA is given more scope to provide broad advice on human nutrition, even outside the strict framework of existing EU legislation. Welcome expansions that will benefit biotech companies and ultimately support innovation, without compromising on safety standards.
Regulatory sandboxes: testing innovation in a controlled environment
In addition to expanding EFSA’s pre-submission advice, the European Commission is introducing regulatory sandboxes through the EU Biotech Act. These sandboxes provide a controlled environment where participants can test innovative products or substances and related processes under a set of defined rules and monitoring and for a limited period of time. Participants can be any natural or legal person. To enable these sandboxes, definitions are being added to article 3 GFL and new articles 49a to 49c GFL are being inserted. These articles govern the establishment, operation and conditions of the regulatory sandboxes.
Regulatory sandboxes enable innovative biotech companies to test their new products and processes in a safe, controlled environment before they enter the market. Rather than having to comply immediately with all existing regulations, participants can experiment with new technologies under the supervision of the authorities whilst simultaneously learning what data and studies are required for full market authorisation. This lowers the barrier to innovation, shortens development time and helps companies better understand what is expected of them, whilst safety and oversight remain guaranteed.
Amendments to the GMO Directive: a tailored framework for micro-organisms
A separate proposal accompanying the EU Biotech Act presents substantial changes to Directive 2001/18/EC on the deliberate release of genetically modified organisms (GMOs) into the environment. With the addition of new articles 24a to 24g, a specific extension for genetically modified micro-organisms (GMMs) within the existing GMO framework is being introduced.
The extension is intended to make the regulatory framework more fit for purpose for GMMs, acknowledging that the existing rules were largely designed with genetically modified plants in mind and do not always align well with the distinct characteristics, applications and risk profiles of micro-organisms. By tailoring Directive 2001/18/EC to the specificities of GMMs, the EU aims to strengthen its attractiveness as a location for their development, production and commercialisation. In particular, low-risk GMMs will benefit from faster market access procedures under the proposed changes. For the food and feed sector, this is widely viewed as a positive development: clearer and more proportionate rules should reduce regulatory uncertainty and lower barriers to market entry, while continuing to ensure a high level of safety. In the agri-food sector, GMMs offer significant potential, e.g. in the development of biofertilisers, biopesticides and biological food preservatives. A more tailored regulatory approach could therefore support innovation in sustainable food production, enhance efficiency and enable the introduction of new products to the market.
EU Food and Feed Safety Simplification Omnibus
The Food and Feed Safety Simplification Omnibus amends ten regulations with three overarching objectives: reducing administrative burdens, accelerating market access for safe products, and modernising outdated procedures. Here’s what’s changing:
Accelerating market access for safe products
Several regulations are moving away from time-limited approvals to unlimited authorisations for substances with proven safety profiles, freeing up regulatory capacity to focus on high-risk substances.
The proposed modification of the Plant Protection Products Regulation (No 1107/2009) introduces unlimited approval periods for active substances (article 5), whilst accelerating market access for biocontrol substances through EFSA’s new role as rapporteur Member State (article 7), priority assessment (article 11), tacit approval after 120 days (article 37), and treating the EU as one zone for products containing only biocontrol or low-risk substances (article 3, point 17). The regulation also provides a clear definition of biocontrol substances as occurring in nature (excluding heavy metals) and substances of biological origin or synthetically produced that are functionally identical and structurally similar. Additionally, article 3, point 36 introduces a definition for basic substances as active substances not predominantly used for plant protection but nevertheless useful in plant protection, with articles 23 and 23a clarifying their approval criteria and allowing their placing on the market without Member State authorisation to ensure easier access for farmers.
Similarly, the proposed modification of the Biocidal Products Regulation (528/2012) introduces unlimited approval duration for active substances (article 4), whilst the proposed modification of the Feed Additives Regulation (1831/2003) follows suit with unlimited authorisations (article 9(8)).
Finally, the proposed modification of the Official Controls Regulation (2017/625) tackles potential delays at borders by allowing border control posts to split consignments of plants and plant products and release parts for which controls are completed (article 50(3)), preventing food waste caused by lengthy laboratory analyses.
Reducing administrative burdens
Multiple regulations are being simplified to reduce unnecessary paperwork and duplicate procedures.
The proposed modification of the Plant Protection Products Regulation removes record-keeping obligations for products containing only biocontrol substances (article 67), whilst the proposed modification of the Biocidal Products Regulation simplifies EU authorisation procedures by publishing only summaries in the Official Journal rather than full decisions (article 44).
The proposed modification of the Feed Additives Regulation modernises labelling requirements by permitting digital labels for non-safety-critical information (article 16) and simplifies administrative changes such as transfers of authorisation holders.
The proposed modifications of the Hygiene Regulations (852/2004 and 853/2004) streamline notification procedures for national measures by adopting one uniform procedure instead of two different procedures, whilst the proposed modification of the Regulation 1099/2009 on animal welfare at slaughter removes duplicate reporting obligations on depopulation operations (article 18, paragraphs 4 and 6), as existing reporting under the Official Controls Regulation is sufficient.
The proposed modification of the Official Controls Regulation introduces flexibility in laboratory accreditation requirements, allowing alternative standards and permitting designation of reference laboratories without full accreditation for all methods under certain conditions (articles 41, 93 and 100), reducing costs whilst maintaining reliability.
Modernising outdated procedures
Several regulations are being updated to reflect current scientific knowledge, international standards and market realities.
Regulation 396/2005 on
maximum residue levels (MRLs) is being amended to set MRLs at zero (limit of quantification) for hazardous substances not approved in the EU (article 14), aligning import standards with EU production standards. Simultaneously, new paragraphs in articles 14 and 18 allow for transitional measures for products subject to the old MRLs, preventing unnecessary food waste. Additionally, article 3(2)(f) is amended to replace the term ‘limit of determination (LOD)’ with ‘limit of quantification (LOQ)’.
The proposed modification of the Regulation 1829/2003 on genetically modified food and feed clarifies that products obtained using genetically modified micro-organisms (GMMs) as production strains are not considered ‘produced from GMOs’ where the GMMs are not present in the final product and any residues are limited to non-viable cells (article 2(10)), resolving long-standing uncertainty for the fermentation sector. This clarification represents a parallel approach to the GMM framework introduced under the EU Biotech Act as discussed above. The EU Biotech Act adapts Directive 2001/18/EC to the specificities of GMMs that are deliberately released or placed on the market for various applications, providing tailored regulatory rules and faster procedures for low-risk micro-organisms. The Food and Feed Safety Simplification Omnibus focuses specifically on GMMs used as production strains for food and feed, ensuring legal certainty for businesses by clarifying when they fall out of scope of the regulation.
The TSE Regulation (999/2001) is being modernised to enable swift updates to BSE control measures through delegated acts (articles 5, 6, 8 and 16) and removes outdated restrictions on gelatine and collagen from ruminant bones (article 16).
Conclusion
The EU Biotech Act and the Food and Feed Safety Simplification Omnibus represent a pragmatic recalibration of EU food and feed regulation. By introducing regulatory sandboxes, expanding EFSA’s advisory role and removing time-limited approvals for proven-safe substances, the European Commission is creating space for innovation whilst maintaining rigorous safety standards.
For food and feed businesses, these proposals offer tangible benefits: faster market access for biocontrol substances and feed additives, reduced administrative burdens through digital labelling and streamlined procedures, and greater legal certainty for fermentation-based products. At the same time, stricter import standards for hazardous pesticide residues and modernised BSE controls demonstrate that simplification does not mean compromising on safety.
The second part of the EU Biotech Act is expected to be released in Q3 2026. Meanwhile, the European Parliament and Council will review the legislative proposals under the Food and Feed Safety Simplification Omnibus, for which a plenary session is planned for March 2026. As these proposals move through the legislative process, business should prepare for a regulatory landscape that rewards innovation, values efficiency and maintains Europe’s reputation for the highest food safety standards. The message is clear: the EU is open for biotech business, but safety remains non-negotiable.
Curious to know what these proposals mean to your business? Let’s get in touch!
This blogpost is written by Karin Verzijden, Jasmin Buijs and Maartje Hop.
Images are by Freepik.
Probiotic health claims remain tricky
Posted: September 11, 2025 Filed under: Advertising, Food, Health claims Comments Off on Probiotic health claims remain tricky“Supports your intestinal flora” sounds harmless. Yet that promise cannot simply be used in advertising. This becomes extra clear in a recent ruling by the Dutch Advertising Code Committee (ACC). In this blog, I will analyse how the ACC reaches its decision, and what it reveals about the scope, or rather the limitations, for such and similar health claims.
The case
The label of the product Beautiful Immunity Kefir Mild contains, among others, the statements that kefir supports the intestinal flora (in Dutch: kefir ondersteunt de darmflora) and that their kefir drinks are high in protein, low in fat and a source of calcium and vitamin B12 (In Dutch: onze Kefir-drankjes bevatten veel eiwitten, weinig vet en zijn een bron van calcium en vitamine B12). Furthermore, two claims are made: calcium and vitamin B12 for your gut health* and support of your immune system** (In Dutch: calcium en vitamine B12 voor uw darmgezondheid* en ondersteuning van uw immuunsysteem**). The label also contains claims about *calcium supporting the normal function of digestive enzymes (in Dutch: *Calcium draagt bij tot de normale werking van spijsverteringsenzymen) and **vitamin B12 supporting the normal function of the immune system (in Dutch: **Vitamine B12 draagt bij tot de normale werking van het immuunsysteem).
Designation kefir mild
According to the complainant, the naming of the product “kefir mild” is confusing consumers. They would think this variant of kefir contains yeasts and alcohol, like the traditional kefir does, but in reality, it doesn’t. The ACC mentions that the advertiser must use a customary or descriptive name for the product. Kefir is designated as a milk product. In the Netherlands, kefir is not a protected product name or a legally established designation, like other dairy products as milk or cheese. According to Beautiful Immunity, a distinction must be made between commercial and traditional kefir. Since shops will mainly sell the commercial variety, which, like “mild kefir”, does not contain yeasts, the ACC does not consider this designation for “mild kefir” to be incorrect or insufficiently specific. The average consumer will think that it is kefir with a mild taste and not traditional kefir with yeasts. Therefore, the naming of the product “kefir mild” isn’t confusing for consumers. The ACC rejects this complaint. Nevertheless, Beautiful Immunity currently designates its product just as “kefir”.
Health claim
Secondly, the complaint states the text displayed on the label contains a misleading health claim. This concerns the claim that the kefir product supports the intestinal flora and contains billions of live cultures. According to the complainant, this suggests a broader effect than the product actually offers, especially since the product does not contain yeasts and does not undergo a traditional fermentation process. The ACC rules that the claim “supports the intestinal flora” qualifies as a health claim. According to article 10 of the Claims Regulation, only authorised health claims can be used. A quick research in the EU Health Claims Register reveals there is no authorised health claim linked to kefir.
Furthermore, article 5(1)(b) of the Claims Regulation requires a health claim to be specifically linked to ingredients or substances. In this case, the advertiser attributes the claimed effect to kefir and not to the ingredients calcium or vitamin B12. More specifically, Beautiful Immunity indicates that the health claim about kefir supporting the intestinal flora is a generic health claim that is accompanied by to the authorised claim for calcium stated on the back of the packaging (article 10(3) of the Claims Regulation).
The ACC does not agree. According to the ACC, the health claim “supports the intestinal flora” is located under the word “kefir” on the front of the packaging. Consumers will read that Beautiful Immunity claims that kefir supports intestinal flora. The name of the product and the health claim follow each other directly and appear to be related. This claim cannot be linked to the claim “Calcium contributes to the normal function of digestive enzymes”. The reason is that the claim is located on the back of the packaging and an asterisk that can clarify the link between the claims is missing. It is therefore an independent health claim, see the ruling of the Court of Justice of 30 January 2020, case C-524/18.
Because there is no authorised health claim for kefir, the health claim that kefir supports the intestinal flora is contrary to article 10(1) of the Claims Regulation. This results in the ACC concluding that this claim is not in accordance with the law as referred to in article 2 of the Dutch Advertising Code, so the ACC upholds the complaint.
For gut health
Beautiful Immunity states that it regularly updates its labelling and that the claim “supports intestinal flora” no longer appears on the new label. Instead, the text “For gut health” is used. This claim is more generic, but if it substitutes the text “supports the intestinal flora”, it is still displayed under the word “kefir”. So, it remains an independent claim about kefir, that is unauthorised. This shows claims about gut health, intestinal flora and probiotics remain tricky.
Intestinal flora and probiotic claims
In this procedure the ACC rules that the health claim that kefir supports the intestinal flora is not permitted and therefore contrary to article 2 of the Dutch Advertising Code. The health claim was actually intended for calcium. What is striking is that the ACC attributes the unauthorised nature of the health claim to the fact that it refers to kefir rather than calcium. The ACC does not assess the admissibility of claims about intestinal flora in general here. Would the health claim “supports the intestinal flora” be permitted if it referred to calcium rather than kefir?
One could argue that in this case article 10(3) of the Claims Regulation is complied with, assuming that the claim is accompanied by the authorised calcium health claim, but caution should still be exercised with health claims about intestinal flora. In the Netherlands, the list of the on hold claims, drawn up by the Dutch Health Advertising Knowledge and Advice Council (in Dutch: Keuringsraad), distinguishes between the categories of digestion and intestinal flora. This suggests that the claim about intestinal flora cannot be accompanied by the authorised claim that calcium contributes to the normal function of digestive enzymes. In fact, there still aren’t any authorised health claims on intestinal flora or probiotics, see our previous blog about probiotic claims.
In the meantime, the European Ombudsman closed a case about probiotic health claims. This case was about the interpretation of the term probiotics by the European Commission. According to the European Commission, the word probiotics suggests a health claim, while the complainant, an association of producers of probiotics, argued that this word rather suggests a nutrition claim. The European Commission intends to protect consumers from potentially misleading information about food. As such, it is not surprising for the Commission to interpret claims about probiotics as health claims. The European Ombudsman accepts the explanation of the European Commission that it does not rule out submitting new applications to authorise probiotic health claims in the future, if the health benefits are scientifically proven.
Conclusion
The ACC rejects the complaint about the name “kefir mild”, as it is accurate and sufficiently specific. The average consumer will think that the term “kefir mild” refers to kefir with a mild taste, and not to traditional kefir containing yeast (including alcohol). The ACC however upholds the complaint regarding the health claim “supports the intestinal flora”. In essence, the ACC rules that consumers would think that the claim is about kefir. And the claim that kefir supports the intestinal flora is an unauthorised health claim. In fact, all health claims about intestinal flora are unauthorised. The same applies to health claims about probiotics. This may change in future, if and when these types of claims are substantiated by scientific evidence regarding the health benefits offered. So, think twice, when selling the health benefits of your gut health product. And of course, I would be happy to help out in case of doubt.
The full case can be read here (in Dutch).
Image: https://nl.beautifulimmunity.eu/
No health claims for botanicals, unless… – implications for the Dutch market
Posted: May 19, 2025 Filed under: Advertising, Food Supplements, Health claims Comments Off on No health claims for botanicals, unless… – implications for the Dutch market
Last April 30th, the European Court of Justice (ECJ) answered the question whether so-called ‘on-hold’ health claims related to botanical substances are permitted (case C-386/23). As covered in an earlier blogpost, this question was submitted to the ECJ by the German Bundesgerichtshof in the summer of 2023. In this blogpost, we discuss the outcome of the case, the transitional regimes of article 28(5) and (6) Claims Regulation, and the implications of the case for the Netherlands.
The case
The question at hand came up during national German court proceedings concerning a food supplement of the company Novel Nutriology, which was advertised as mood enhancing and reducing feelings of stress and fatigue thanks to its extracts of saffron and melon juice. Health claims for botanical substances like the above are currently on-hold, since the European Commission has not yet completed its examination of such claims for the purposes of their inclusion in the positive lists of authorized health claims. Due to the absence of botanical-related claims on these lists, such claims can therefore not be used based on article 10(1) and (3) Claims Regulation. It namely follows from this article that the use of a specific health claim is only permitted if it is included on one of the positive lists, and any generic health claim must be accompanied by such a specific claim. The referring court therefore wanted to know whether it is indeed prohibited to promote botanicals with health claims as long as such claims are not included on the positive lists.
Prohibited, unless….
The ECJ confirmed that until inclusion of the so-called on-hold claims on the positive lists, it is prohibited to promote botanicals using health claims. This is however different if the use of such claims is permitted under the transitional measures provided for in article 28(6) Claims Regulation. Unlike earlier speculations, this applies not only to specific (art. 10(1)) claims but also to generic (art. 10(3)) claims. In other words: generic health claims for botanicals are prohibited, unless they are accompanied with a specific claim that meets the requirements of the transitional regime. Since the referring court starts from the premise that the health claims at issue are psychological claims, we note that the ECJ only covers such claims and no physiological function claims in its ruling, on which more later.
Transitional measures deepened
Article 28 of the Claims Regulation includes transitional measures that were intended to enable food businesses to adapt to the requirements of the regulation when it became applicable back in 2007. The transitional measures in art. 28(5) and (6) Claims Regulation however also apply to the botanical-related health claims that are currently still on-hold. This is made explicit in recitals 10 and 11 of Regulation 432/2012, which establishes a list of authorized function health claims (also known as Article 13 claims). As referred to by the ECJ in its ruling, the foregoing also follows from recital 9 of Regulation 536/2013, which amends Regulation 432/2012.
Article 28(5) and (6) Claims Regulation set forth different transitional regimes for respectively physiological function claims and other health claims. As relevant for the type of health claims made by Novel Nutriology, the ECJ applies the test set forth in article 28(6). The first question to be answered is whether the health claim has been used in compliance with national provisions before the date of entry into force of the Claims Regulation. Based on the input of the referring court, the ECJ relies here on the premise that this is the case. The claim can therefore continue to be used, provided that it either has been subject to evaluation and authorization in a Member State, or has been submitted for EU authorization prior to 19 January 2008.
Although not specified by the ECJ, it does not seem a requirement that the food business at stake has been using the claim before the data of application of the Claims Regulation itself and has, where relevant, made itself an application for authorization. The literal text of article 28(6) Claims Regulation does also not require this as it doesn’t specify the required user or applicant. A food business that wishes to use an on-hold claim does therefore not need to be the original user and applicant of the claim.
Novel Nutriology nevertheless fails to comply with the requirements of article 28(6). As was noted by the referring court, the health claim related to the saffron extract was the subject of a late application past the deadline set in the transitional measures. For the melon extract claim, no application has been submitted at all. Novel Nutriology can therefore not make the health claims at stake.
What about physiological function claims?
While the ECJ did not see reason to elaborate on the transitional measures for physiological function claims as dealt with in article 28(5) Claims Regulation, the Advocate-General does indicate in his Opinion what if the respective health claims were to be considered as such. These claims may than continue to be used under the conditions set forth in that article so long as the positive list of health claims has not been adopted in respect of botanical substances.
The question however remains whether generic claims accompanied with physiological function claims can be made under the applicable transitional measures to promote botanicals. An analogical application of the ECJ’s ruling to the transitional measures of article 28(5) Claims Regulation suggests that this should be possible, which is also the conclusion of the Advocate-General in his Opinion. A difference between article 28(5) and 28(6) Claims Regulation is however that the former explicitly refers to physiological function claims as meant in article 13(1)(a) Claims Regulation, whereas the latter covers “health claims other than those referred to in Article 13(1)(a) and in Article 14(1)(a)”. In accordance with this European implementation assessment, it may therefore as well be concluded that generic claims are not dealt with under the transitional measures of article 28(5). Whether such a strict (literal) interpretation should indeed be applied, remains unanswered.
Implications for the Netherlands
As explained in our earlier blogpost on this topic, health claims for botanicals are accepted in the Netherlands if the roadmap of the Dutch agency regulating health products (the Keuringsraad) in cooperation with the Dutch food safety authority (NVWA), is met. Also the NVWA Handbook on Nutrition and Health Claims provides a detailed guidance on the use of on-hold claims for botanical substances.
While the roadmap and NVWA handbook only accept on-hold claims with an ID number that is present on the so-called ‘on-hold’ list, we notice that in practice little attention is paid to the exact requirements of the transitional measures under the Claims Regulation. The ruling at stake may therefore be seen as a wake-up call for compliance. We recognize at the same time that it may not always be easy to prove e.g. that an on-hold claim has been used in compliance with national provisions before the date of entry into force of the Claims Regulation. So far we have not seen enforcement on this point, so future will have to tell whether this may change.
We further notice that the topic of generic claims that are substantiated with on-hold claims is not covered in the Dutch guidance materials. The case at stake however taught us that this also falls under the transitional regime of article 28(6) Claims Regulation. Since it remains unclear how this plays out under the transitional regime of article 28(5), it would be helpful for businesses if the Dutch enforcement body can share its take on this in its Handbook.
Conclusion
When it comes to psychological and behavioral function claims, the case at stake clarifies that the transitional measures of the Claims Regulation apply both to specific and generic claims. How this plays out for physiological function claims has not been covered by the ECJ, and could be argued different ways. It would be helpful if this question could therefore be answered in national guidance materials, and until that time we recommend that food businesses have a robust legal justification for their interpretation of the transitional measures, if these are what they rely on for their use.
Images are by freepik.
Is it allowed to use meaty names for meat substitutes?
Posted: September 6, 2024 Filed under: Food Comments Off on Is it allowed to use meaty names for meat substitutes?
On 5 September 2024, Advocate General (AG) Capeta rendered her opinion in the case initiated by Protéines France, Union Végétarienne, Beyond Meat and others against the French state, disputing a French national Decree limiting the use of meaty names for meat replacements. This Decree dates back to 2022, implementing a specific article of the French Consumer Code. According to this article, the names used to designate foods of animal origin cannot be used to describe, market or promote foods containing vegetable proteins.
Two French Decrees
This Decree was immediately under fire by the same parties mentioned above before the French Council of State. According to them, the Decree was unlawful since, roughly speaking, the subject matter was fully harmonized at EU level by the Food Information to Consumers Regulation (FIC Regulation). The French Council of State then stayed the proceedings to ask four explanatory questions to the European Court of Justice (ECJ). Meanwhile, France repealed the 2022 Decree replacing it by a 2024 Decree, essentially similar to the previous one. The question then arose if the request for a preliminary ruling became devoid of purpose. The good news is that according to the AG this is not the case, essentially because the Council of State had informed the ECJ that the interpretation sought remained necessary to enable it to rule on the dispute in the mean proceedings.
System of 2024 Decree
The system of the 2024 Decree is twofold. First, it establishes a list of terms of the use of which is prohibited for the designation of foods containing vegetable proteins (examples: entrecôte, steak, jambon). Second, it authorizes the use of certain terms for the designation of foods of animal origin containing vegetable proteins, provided they do not exceed a certain proportion (examples: cordon bleu (maximum 3,5 % vegetable protein), merguez (maximum 2 % vegetable protein of which 1 % should consist of herbes), terrine de campagne (maximum 5 % of vegetable protein). Products legally manufactured or marketed in another Member State of the European Union or in a third country are not subject to the requirements of this Decree. French companies are however subject to a fine of € 7.500 if they act in violation thereof.
International context
These days, France is not the only Member State where naming issues of meat replacements arise. In fact, in several EU countries such as Italy, Poland and Romania, similar rules as in France have been adopted. Also outside the EU like in the US, in South-Africa and in Switzerland, similar legislative initiatives took place. At the same time, in countries like the Netherlands and in Germany, measures have been adopted expressly allowing the use of meaty names for non-meat products, specifically aiming to prevent any misleading of consumers. For example, in the Netherlands a product can be legally sold under the designation of “vegaschnitzel” (vegetarian Schnitzel) or “vegetarisch krabsalade” (vegetarian crab salad). So, it is about time to have a decision on this topic at European level. Should we be happy with the opinion of AG Cadeta? This most likely depends which side you are on. If you are a manufacturer of conventional meat products, this opinion will most likely meet your approval. If you are a food innovator, proposing alternatives to conventional meat, you will most likely be disappointed. This is why.
AG does not consider use of substitute products harmonized at EU level
The basic question in this debate is whether European legislation has specifically harmonized the naming of substitute products. According to the AG, this is not the case. As a consequence, this leaves room for Member States for establishing legal names, reserving those names for particular foods. Legal names should be distinguished from customary or descriptive names according to their intended effect. If the effect of national rules is that certain names are reserved for certain types of products, then they qualify as legal names. By adopting national measures prohibiting the use of certain customary and descriptive names, including when they are accompanied by additional indications that the product at issue contains plant-based, instead of meat-based, proteins, a Member State turns those customary and descriptive names into legal names. This is precisely the effect of the 2024 Decree and Member States are entitled to do so. The AG goes on to reason that the FIC Regulation does not preclude Member States from adopting national measures according to which meat replacement products can only have a maximum of vegetable proteins when using meaty names. Relevant here is that a distinction is made between domestic production and production abroad. In fact, the 2024 Decree stipulates that its rules do not apply to any imported products. The AG therefore considers the France Decree a purely internal matter. Finally, national administrative penalties sanctioning this regime are not counter to the FIC Regulation.
FIC Regulation does provide for harmonization of replacement products
I do not dispute that Member States can establish legal names at national level; this follows indeed from the FIC Regulation. This may be suitable in the context that food is highly cultural – certain dishes are found in one Member State and not in the other. This is the cultural wealth of Europe, where you only need to travel a few hundred kilometers to find entirely different landscapes, languages and cultural habits. I have however troubles to digest the conclusion that because of the fact that Member States can establish legal names for their specific food products, the subject matter would not be specifically harmonized at EU level. In fact, the FIC Regulation specifically addresses the topic of replacement products in its Annex VI. According to the AG, the rule laid down therein covers the use of meaty names for plant-based substitute products. From the Tofutown decision she however draws the learning that the Annex VI rule only applies if the meaty name is not a legal name. The difference between that case and the present one is that the legal names prohibiting the use of dairy names for dairy replacement products were embodied in the COM Regulation. This is specific harmonization at EU level indeed. In my view, it is questionable if legal names at national level that were newly established for a specific goal (see below) should be attributed the same weight as legal names that have been around for long at EU level, also taking into account the consequences thereof. This is all the more so, now that legal names are usually not prohibited terms as in the 2024 Decree, but positively phrased (example: “The beef and veal sector shall cover the products in the following table: live animals of the domestic bovine species… meats of bovine animals… fats of bovine animals….” – see COM Regulation Annex I, Part XV).
Consequences if ECJ adopts opinion AG Cadeta
If the ECJ embraces this opinion in its decision, there is a good chance that the 2024 Decree will stay in effect and will be enforced in France. Therefore, France national manufacturers of meat substitutes will be very much limited in the designation of their products. As such, they will be put at disadvantage in comparison to manufacturers in countries without such limitative legislation. Furthermore, other Member States having similar legislation in place most likely will feel confirmed in their policy and also enforce these provisions in their home turf. Companies formulating innovative food products thereby get the short end of the bargain on an EU wide basis. And this is not how the internal market was meant.
Two basic principles of internal market under threat
Two starting principles of the internal market are the free circulation of goods and a high level of consumer protection. Allegedly, the rationale behind the French Decrees was consumer protection. The AG explicitly addresses this topic. She states that it does not matter if the French authorities intended to protect consumers or the meat industry, or whether the reason behind such rules is the protection of national gastronomical heritage. At first sight, such a neutral approach could possibly make sense. At second sight, I tend to disagree. In the first place, because experience in the Netherlands has shown that consumers are not misled if meaty names are used for meat replacements. While the Netherlands may be considered very progressive in this regard, it was already established by ProVeg research in 2022 that plant-based labels do not confuse consumers. Secondly, restrictive measures are not needed to protect a certain industry or cultural heritage, since substitute products are not meant to entirely replace conventional meat products. Instead, they offer additional choice to the consumer, who decides to eat less or no meat. This should by no means be a threat to the meat industry, but an increase of food options for consumers. Exactly the purpose of the internal market.
For the reasons set out above, I sincerely hope that the ECJ will not adopt the current opinion of AG Capeta.
Credits image: Vegconomist, 11 April 2024











